Signature Rx, Delray Beach, FL
Is Signature Rx an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Signature Rx in Delray Beach, FL, first registered Oct 13, 2023 and most recently registered Aug 31, 2026. FDA lists it as not yet inspected.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Delray Beach, FL
- Initial registration
- Oct 13, 2023
- Most recent registration
- Aug 31, 2026
- Last inspection
- Not yet inspected
- Form 483 issued at last inspection
- N/A
- Recall after last inspection
- N/A
- Action on last inspection
- N/A
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Signature Rx). That is not a finding beyond this index’s search.
The Signature Rx pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming semaglutide under the labeler name “Signature Rx”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 84582-4104 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 4 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.